Biotech Startups

Kanaphterapeutics is a pharmaceutical company developing synthetic drugs and antibody-based therapeutics for cancer treatment using proprietary human genome analysis and ADC (antibody-drug conjugate) technologies.

2 investors

Kangstem Biotech is a South Korean biotechnology company developing stem cell-based therapeutics for rare and intractable diseases, including its FURESTEM-OA product for osteoarthritis. It also operates a CDMO (contract development and manufacturing) business and conducts related R&D.

2 investors

Kanjin Therapeutics is a biotechnology startup developing treatments to restore kidney function and address chronic kidney diseases, using a strategy of targeting the liver. Founded as a scientific spinout from Okayama University, it operates across the US and Japan.

2 investors

A clinical-stage life sciences company developing therapeutics for unmet needs in sexual and mental health, including a lead program aimed at becoming the first FDA-approved treatment for premature ejaculation and a pipeline targeting mood disorders.

2 investors

Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease. The company integrates AI and real-world data to advance clinical development across multiple underserved cardiovascular conditions.

2 investors

Kare Chemical Technologies is a pharmaceutical technology company using a patented catalytic process to convert limonene, a citrus by-product, into high-purity CB1 and CB2 receptor ligands for drug development. It develops non-psychoactive therapeutic candidates aimed at safer alternatives to opioids and next-generation metabolic therapies.

2 investors

Karis Bio develops therapies based on human induced pluripotent stem cells (hiPSCs) to treat cardiovascular diseases, with initial focus on peripheral arterial disease and critical limb ischemia. The company targets vasculogenesis-related conditions such as ischemic heart disease, diabetic retinopathy, diabetic neuropathy, and wound healing.

2 investors

Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers. Its work centers on inhibiting the MDM2-p53 interaction as a therapeutic target in oncology.

2 investors

Karyosoft is a no-code genomics platform for secondary and tertiary NGS analytics, designed for agricultural biotechnology researchers, universities, and bioinformatics teams. It enables scientists to analyze genomic datasets without coding expertise while maintaining data security and standardizing research workflows.

2 investors

A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.

2 investors

KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs. It uses an integrated discovery and development platform, including a pharmacology experimental platform, to advance differentiated drug candidates from bench to clinic.

2 investors

A biopharmaceutical company developing targeted cancer drugs and related therapies. The company focuses on drug discovery, clinical development, and commercialization to address unmet oncology needs in China and globally.

2 investors

Company co-founded in 2022 by Dr. Lau and Jason Bourgeois.

2 investors

Kelonia is a biotechnology company developing next-generation genetic medicines, with a focus on cell and gene therapy programs including in vivo approaches and oncology applications. It advances therapeutic programs from preclinical research through clinical development.

2 investors

KelSie Biotech is a biotechnology company developing and commercializing drug-delivery technologies licensed from Sievers Biotech, including a Bubble Drying Process, sublingual wafers, and dry powder inhalable products. The company holds worldwide rights to formulate, sell, and sublicense finished products based on this technology and intellectual property.

2 investors

Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.

2 investors

Kentegra produces concentrated liquid insecticidal extracts derived from pyrethrum flowers for use in household, agricultural, animal health, and public health pest control applications. The company's products are naturally derived, photo-degradable active ingredients suitable for formulation into consumer and professional pest management products.

2 investors

Kern Systems develops DNA-based data storage, using enzymatic DNA synthesis and custom digital codecs to encode information. It aims to build scalable information infrastructure stored in DNA as an alternative to current memory technologies.

2 investors

Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

2 investors

Keyron develops ForePass, a fully endoscopic, non-invasive and reversible gastric bypass medical device intended to reproduce the effects of metabolic surgery for patients with Class II & III obesity, type 2 diabetes, MASH/NASH, and liver fibrosis. The company targets severe "diabesity" patients who refuse surgery or do not achieve results with drugs, across the US and EU5 markets.

2 investors

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. It operates in the biopharmaceutical and therapeutics sector.

2 investors

Kind Biotechnology develops the ION platform, which uses artificial genomic constructs to grow interconnected peripheral organs for xenotransplantation. The company aims to address organ scarcity in transplant medicine to treat age-related organ failure and extend healthy human lifespan.

2 investors

Kiniciti is a platform company that operates cell and gene therapy-focused life science businesses, including Cellistic for iPSC-based manufacturing technologies and Ncardia for human iPSC products and drug discovery services. The company serves therapeutic developers and pharmaceutical companies seeking scalable cell therapy manufacturing and drug discovery solutions.

2 investors

Kinoxis Therapeutics develops novel therapeutics targeting inflammatory signaling pathways in the nervous system to address unmet needs in CNS disorders, with initial focus on treatments for agitation and pain.

2 investors